Geoffrey Shapiro
Medical Oncology · Boston, MANPI 1255309316
Payments from drug & device makers
Across 808 payments — averaging $19,881 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$9.4M
- Amgen$1.9M
- Merck Healthcare Kgaa$800K
- Novartis$564K
- Bayer$498K
- Eli Lilly$469K
- plus $2.5M from 26 others
Across 13 payments — averaging $10,430 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$110K
- Eli Lilly$25K
- Takeda Pharmaceuticals U.S.A., Inc.$200
- E.r. Squibb & Sons, L.L.C.$90
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer(2 entities) | 174 | $9,397,475 |
| Amgen | 36 | $1,864,238 |
| Merck Healthcare Kgaa | 3 | $800,000 |
| Novartis | 9 | $563,988 |
| Bayer | 78 | $498,087 |
| Eli Lilly | 25 | $468,967 |
| Exelixis Inc. | 129 | $444,498 |
| Astrazeneca UK Limited | 3 | $335,868 |
| Boehringer Ingelheim | 4 | $300,119 |
| Clovis Oncology, Inc. | 23 | $244,375 |
| Merck | 14 | $239,217 |
| AstraZeneca | 11 | $205,053 |
| Puma Biotechnology, Inc. | 16 | $198,858 |
| Modernatx, Inc. | 1 | $125,000 |
| Incyte Corporation | 141 | $79,540 |
| Otsuka Pharmaceutical Co., Ltd. | 5 | $77,849 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67,325 |
| Seagen Inc. | 9 | $59,842 |
| GSK | 2 | $34,301 |
| Medivation LLC. | 4 | $14,500 |
| Mirati Therapeutics, Inc. | 3 | $10,400 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 28 | $7,144 |
| EMD Serono Research & Development Institute, Inc. | 1 | $6,750 |
| Tesaro, Inc. | 1 | $6,052 |
| SCS Boehringer Ingelheim Comm.v | 73 | $5,276 |
| Boehringer Ingelheim International GmbH | 3 | $3,075 |
| Taiho Oncology, Inc. | 1 | $1,718 |
| Blueprint Medicines Corporation | 1 | $1,680 |
| Genentech, Inc. | 3 | $1,594 |
| AbbVie | 1 | $1,058 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $200 |
| Gilead | 1 | $12 |
How this compares
$16,064,059 in reported general payments places this provider in the 95th percentile of 308 medical oncology providers in Massachusetts.
Other medical oncology in Boston
- Otto MetzgerBoston$141.9M
- Suzanne GeorgeBoston$88.5M
- Pasi Antero JanneBoston$67.2M
- Erica MayerBoston$51.8M
- Toni ChoueiriBoston$28.3M
- Laura SpringBoston$22.9M
- James ClearyBoston$18.8M
- Marlise LuskinBoston$18.7M
- Ana Garrido-CastroBoston$18M
- Jacob LaubachBoston$17.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.